



I131-apamistamab SIERRA abstracts accepted for oral and poster presentation at the European Association of Nuclear Medicine 2023 Congress

Stockholm, August 25, 2023 – Immedica’s partner Actinium Pharmaceuticals, Inc. has announced that two abstracts have been accepted for oral and poster presentation at the upcoming European Association of Nuclear Medicine (EANM) 2023 Congress, which will be held in Vienna, September 9-13, 2023. The EANM oral presentation represents the fifth oral presentation at prestigious medical conferences globally in 2023 including TCT, EBMT, SNMMI, and EHA. The presentation reflects that I131-apamistamab increases access to allogeneic hematopoietic stem cell transplant for patients with relapsed or refractory AML with few or no remaining treatment options.

Details of the EANM oral presentation:

Presentation Title: “Safety and dosimetry evaluation of personalized dose I131-apamistamab prior to HCT in the phase 3 SIERRA trial for patients with relapsed/refractory acute myeloid leukemia (R/R AML)”

Session: Theranostics Track - Oncology & Theranostics Committee / EARL - Featured Session: Old but Novel Techniques

Date and Time: September 10, 3:00 pm CEST

Details of the EANM e-poster presentation:

All e-posters will be accessible for viewing for the entirety of the conference.

E-Poster Title: Feasibility of high-dose targeted radiation with I131-apamistamab in patients with relapsed/refractory AML: Dosimetry and radiation safety experience from the phase 3 SIERRA trial

E-Poster Number: EP-0608

Session Title: C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C15 Other Oncological Treatments

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Actinium’s clinical pipeline is led by targeted radiotherapies that are being applied to targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a bone marrow transplant

(HSCT), gene therapy or adoptive cell therapy, such as CAR-T, to enable engraftment of these transplanted cells with minimal toxicities. <http://www.actiniumpharma.com/>.

About Immedica Pharma

Immedica is pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory and medical affairs as well as market access. Serving patients in more than 50 countries, Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need.

Immedica's therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 90 people across Europe and the Middle East.

For more information visit www.immedica.com

Immedica contact:

Linda Holmström
Head of Communication
linda.holmstrom@immedica.com
+ 46 708 73 40 95

Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm